Adhiraj Lanba

FGF21 does not require adipocyte AMP-activated protein kinase (AMPK) or the phosphorylation of acetyl-CoA carboxylase (ACC) to mediate improvements in whole-body glucose homeostasis

J. Granneman, B. Kiens, G. Steinberg, 2017, Molecular metabolism.

Discovery and characterization of novel inhibitors of the sodium-coupled citrate transporter (NaCT or SLC13A5)

P. Loria, T. Rolph, D. Hepworth, 2015, Scientific Reports.

Optimization of a Dicarboxylic Series for in Vivo Inhibition of Citrate Transport by the Solute Carrier 13 (SLC13) Family.

T. Rolph, M. Hayward, D. Erion, 2016, Journal of medicinal chemistry.

Inhibition of Acetyl-CoA Carboxylase 1 (ACC1) and 2 (ACC2) Reduces Proliferation and De Novo Lipogenesis of EGFRvIII Human Glioblastoma Cells

J. Pfefferkorn, Nicholas B. Vera, C. Vernochet, 2017, PloS one.

A Long-Acting FGF21 Molecule, PF-05231023, Decreases Body Weight and Improves Lipid Profile in Non-human Primates and Type 2 Diabetic Subjects.

Jeffrey R. Chabot, J. Trimmer, T. Rolph, 2016, Cell metabolism.

Discovery of a Selective Covalent Inhibitor of Lysophospholipase-like 1 (LYPLAL1) as a Tool to Evaluate the Role of this Serine Hydrolase in Metabolism.

K. Fennell, J. Pandit, K. Parris, 2016, ACS chemical biology.